Coherus Hires Oppenheimer to Sell Legacy Biosimilar Assets
CHRS is trading near its 52-week low of $1.09 (14% above the low).
Summary
Coherus has formally begun marketing its remaining biosimilar assets and retained Oppenheimer & Co. as financial adviser. This follows the August 17 CVR dividend tied to future monetization of those assets. The stock is down 4% at $1.25, reflecting uncertainty about the sale proceeds. The company's Q2 cash of $105.3M was already tight, and this sale is a key step to unlock value for CVR holders. Watch for any announced buyer or terms, which will directly determine the CVR payout.
At the time of this announcement, CHRS was trading at $1.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $192.4M. The 52-week trading range was $1.09 to $2.62. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.